Daiichi Sankyo's Ranbaxy purchase takes step forward
This article was originally published in Scrip
Executive Summary
Daiichi Sankyohas completed the payment of around ¥170.5 billion ($1.70 billion) in relation to its planned purchase ofRanbaxy Laboratories. The sum was paid following the completion last month of an oversubscribed Rs737 ($15.20) per share open offer for 20% of the Indian firm. Daiichi Sankyo is aiming to acquire at least 50.1% of Ranbaxy through a combination of the offer (which involved around 92.5 million shares), the purchase of some 129.9 million shares from the controlling Singh family, a preferential allotment of 46.3 million shares and a subscription of warrants (23.8 million shares).
You may also be interested in...
Quick Listen: Scrip’s Five Must-Know Things
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
Japan Regulators Kept On Track Despite Pandemic
While it was not as affected as some other countries, Japan still had the pandemic to deal with and regulators responded while managing to keep up regular product review work, including several world-first approvals. Coronavirus vaccine roll-outs and the first general annual reimbursement price cut are on the cards for this year.
Quick Listen: Scrip’s Five Must-Know Things
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
Need a specific report? 1000+ reports available
Buy Reports